Other Science

Quanterix’ Kevin Hrusovsky to Present at the Cowen 41st Annual Health Care Conference on March 3 and Appear on the Feb. 26 Episode of the Health Care Rounds Podcast

Thursday, February 25, 2021 - 11:05pm

Replays of the webcast will be available on the Quanterix website for 90 days following the conference.

Key Points: 
  • Replays of the webcast will be available on the Quanterix website for 90 days following the conference.
  • Additionally, Hrusovsky will appear on the Feb. 26 episode of the Health Care Rounds Podcast , a weekly podcast for health care leaders at the forefront of delivery and reform.
  • The episode, Rebuilding Public Trust in Health Care with Kevin Hrusovsky, will discuss precision health and its role in helping to rebuild public trust amid the ongoing coronavirus pandemic.
  • Quanterix is a company thats digitizing biomarker analysis with the goal of advancing the science of precision health.

Dicerna Announces Full Year 2020 Financial Results and Provides a Business Update

Thursday, February 25, 2021 - 9:05pm

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the Company or Dicerna), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the full year ended Dec. 31, 2020 and provided a corporate update.

Key Points: 
  • Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the Company or Dicerna), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the full year ended Dec. 31, 2020 and provided a corporate update.
  • Clinical Development Candidate DCR-AUD for Alcohol Use Disorder (AUD) To Enter Clinical Development in the Third Quarter of 2021.
  • Today, Dicerna announced its third wholly owned clinical development program, an investigational therapy based on Dicernas GalXC technology for the treatment of AUD.
  • ET today to review Dicerna's full year 2020 financial results and provide a general business update.

CM Life Sciences II Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Closing of $276 Million Initial Public Offering

Thursday, February 25, 2021 - 9:01pm

The units are listed on The Nasdaq Capital Market (Nasdaq) and began trading under the ticker symbol CMIIU on February 23, 2021.

Key Points: 
  • The units are listed on The Nasdaq Capital Market (Nasdaq) and began trading under the ticker symbol CMIIU on February 23, 2021.
  • The Company, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, is led by Chief Executive Officer Eli Casdin and Chairman Keith Meister.
  • The Company intends to focus its search for business combination targets in three separate areas of the life sciences industry that are often fragmented life sciences tools, synthetic biology and diagnostics.
  • This press release contains statements that constitute forward-looking statements, including with respect to the anticipated use of the net proceeds.

Economic Burden of Rare Diseases in the U.S. Approached $1 Trillion in 2019, Surpassing Cost Estimates for Many Chronic Diseases

Thursday, February 25, 2021 - 6:28pm

While there are estimated to be more than 7,000 rare diseases, The National Economic Burden of Rare Disease Study includes 379 rare diseases in its assessment.

Key Points: 
  • While there are estimated to be more than 7,000 rare diseases, The National Economic Burden of Rare Disease Study includes 379 rare diseases in its assessment.
  • This estimate sheds light on a set of costs that previous studies did not examine across rare diseases.
  • The report estimates that 15.5 million individuals in the U.S. have any of the 379 rare diseases included in the study.
  • The study authors caution that their economic impact estimate represents a conservative estimate and is not generalizable to all rare diseases.

Foresite Capital Raises $969 Million to Invest in Early to Late-Stage Companies Transforming Healthcare

Thursday, February 25, 2021 - 7:00pm

The offering comprises Foresite Capital Fund V, L.P. and Foresite Capital Opportunity Fund V, L.P. With these new funds, Foresite Capital is investing in emerging healthcare and life sciences companies at all stages that are solving some of the biggest inefficiencies and pain points of the $10 trillion global healthcare market.

Key Points: 
  • The offering comprises Foresite Capital Fund V, L.P. and Foresite Capital Opportunity Fund V, L.P. With these new funds, Foresite Capital is investing in emerging healthcare and life sciences companies at all stages that are solving some of the biggest inefficiencies and pain points of the $10 trillion global healthcare market.
  • We believe that many of the household healthcare brands of the future will emerge from this crisis, and Foresite Capital will be there to support them, said Jim Tananbaum, founder and CEO of Foresite Capital.
  • With Fund V, Foresite Capital plans to invest in companies, spanning all stages, that are focused on therapeutics, life science infrastructure and individualized healthcare.
  • In October 2019, Foresite Capital launched Foresite Labs , an incubator that builds and scales transformative companies at the intersection of data science and healthcare.

Worldwide Immunoassay Industry Strategies and Trends to 2025 - Changing Technologies Spur Early Instrument Retirement - ResearchAndMarkets.com

Thursday, February 25, 2021 - 4:26pm

3.1.2 Changing Technologies Spur Early Instrument Retirement.

Key Points: 
  • 3.1.2 Changing Technologies Spur Early Instrument Retirement.
  • 3.3.2 Declining Cost of Instruments Changes Industry Structure.
  • Dx Companies Look at Multiplex Tests for SARS-CoV-2, Influenza
    6.2.4 Global Market by Application Segment Base vs.
  • Final
    6.3.4 Global Market by Technology Segment Base vs.

Break Through Cancer Launches Collaborative Model Across Top U.S. Research Institutions in Pursuit of Cancer Cures

Thursday, February 25, 2021 - 4:00pm

Multidisciplinary research teams will be selected from across five participating institutions: Dana-Farber Cancer Institute, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and the Koch Institute for Integrative Cancer Research at MIT.

Key Points: 
  • Multidisciplinary research teams will be selected from across five participating institutions: Dana-Farber Cancer Institute, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and the Koch Institute for Integrative Cancer Research at MIT.
  • Break Through Cancers model builds on the outstanding efforts of the broader cancer research community and presents the potential for major advances in our shared fight against these intractable cancers, said Dr. Jacks, President of Break Through Cancer.
  • Break Through Cancer ( www.breakthroughcancer.org ) is a public foundation that brings several of the top cancer research centers together to collaborate on and accelerate research, clinical trials, and ultimately cures for the deadliest cancers.
  • Break Through Cancer is currently partnering with Dana-Farber Cancer Institute, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and the Koch Institute for Integrative Cancer Research at MIT.

$5.4 Billion Biopreservation Markets: Cells, Tissues & Organs - Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026 - ResearchAndMarkets.com

Thursday, February 25, 2021 - 2:51pm

The "Biopreservation Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biopreservation Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global biopreservation market reached a value of US$ 5.4 Billion in 2020.
  • Biopreservation refers to the process of preserving cells, tissues or organs outside of their native environment for extended period of time.
  • Looking forward, the publisher expects the global biopreservation market to exhibit strong growth during the next five years.

Structural Biology and Molecular Modeling Techniques Market Research and Outlook Report 2020-2021 - Global Trends, Growth Opportunities and Forecasts to 2028 - ResearchAndMarkets.com

Thursday, February 25, 2021 - 2:40pm

The "Structural Biology and Molecular Modeling Techniques Market Research and Outlook, 2020 - Trends, Growth Opportunities and Forecasts to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Structural Biology and Molecular Modeling Techniques Market Research and Outlook, 2020 - Trends, Growth Opportunities and Forecasts to 2028" report has been added to ResearchAndMarkets.com's offering.
  • Structural Biology and Molecular Modeling Techniques market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Structural Biology and Molecular Modeling Techniques market types and applications.
  • It is a focused study on Structural Biology and Molecular Modeling Techniques market space including global and regional eight-year forecasts for revenues as well as proffers detailed snapshots of country-wide Structural Biology and Molecular Modeling Techniques market revenues.
  • The Structural Biology and Molecular Modeling Techniques market report presents key trends and dynamics making an impact on the Structural Biology and Molecular Modeling Techniques companies across the Americas, Europe, Asia Pacific, and Other markets and provides innovative approaches to stay ahead of the competition in the opportunity-rich Structural Biology and Molecular Modeling Techniques market.